Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors
Conditions
Brief summary
This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma and urinary tract tumors, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.
Interventions
DRUGJMT108
Intravenous (IV) administration
Sponsors
Shanghai JMT-Bio Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label, multicenter Phase I/II clinical study
Intervention model description
This is an open-label, multicenter Phase I/II clinical study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age≥18 years old. 2. Histologically or cytologically confirmed unresectable locally advanced or metastatic melanoma and urinary tract tumors. 3. Participants with unresectable locally advanced or metastatic melanoma or urinary tract tumors who have failed prior standard treatment or have no available standard treatment will be enrolled in Phase I; those who have received or not received prior standard treatment will be enrolled in Phase IIa and Phase IIb. 4. According to the response evaluation criteria for solid tumors (RECIST 1.1), having at least one measurable lesion. 5. ECOG PS of 0-1. 6. Expected survival ≥ 3 months. 7. Participants with adequate organ functions. 8. Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 6 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before the first dose or randomization. 9. Voluntarily agree to participate in the study and sign the informed consent.
Exclusion criteria
1. Within 4 weeks prior to the first administration of the investigational drug, the patient had received chemotherapy, radiotherapy, biologic therapy, endocrine therapy, targeted therapy (excluding small-molecule targeted drugs), immunotherapy, or other unmarketed investigational drugs or treatments; for small-molecule targeted drugs, use was within 2 weeks prior to the first administration of the investigational drug or within 5 half-lives of the drug (whichever is longer, not exceeding 4 weeks); and antitumor-indicated traditional Chinese medicine/products were used within 2 weeks prior to the first administration of the investigational drug. 2. Prior use of IL-2/IL-15 cytokine therapy. 3. Received major organ surgery (excluding needle biopsy) or experienced severe trauma within 4 weeks prior to the first administration of the study drug, or requires elective surgery during the study period. 4. Received systemic glucocorticoids or other immunosuppressive therapy within 14 days prior to the first use of the study drug. Exceptions include the following situations: receiving physiological replacement doses of hydrocortisone or other equivalent doses of hormonal therapy (i.e., prednisone ≤ 10 mg/day or other equivalent doses of hormones); receiving topical, ophthalmic, intra-articular, intranasal, and inhaled glucocorticoid therapy; receiving short-course glucocorticoids for preventive treatment (e.g., prevention of contrast agent allergy). 5. Known active central nervous system (CNS) metastases and/or leptomeningeal metastases. Patients with stable brain metastases who do not require local treatment for brain metastases are eligible for inclusion. 6. Patients with active infections requiring intravenous anti-infective therapy within 14 days prior to the first administration. 7. Has a history of severe cardiovascular and cerebrovascular diseases. 8. Has active or recurrent autoimmune diseases. 9. Has a known history of receiving immunotherapy with the occurrence of grade ≥3 immune-related adverse events (irAEs) (excluding immune-related endocrine abnormalities that have been stabilized) or grade ≥2 immune-related myocarditis. 10. Has a history of arterial or venous thrombosis within 6 months prior to the first administration. 11. Has a history of serous effusions such as ascites or pleural effusion requiring drainage within 14 days prior to the first administration. 12. Has a history of other malignant tumors within 5 years prior to the first administration or concurrent other malignant tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Limiting Toxicity (DLT) (Phase I) | Approximately 28 days. | To evaluate the safery of JMT108 in subjects. |
| Adverse Events (AEs) (Phase I) | Through study completion, an average of 1 year | To evaluate the safery of JMT108 in subjects. |
| Overall Response Rate (ORR) (Phase II) | To evaluate the efficacy of JMT108 in subjects. | Through study completion, an average of 1 year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) | Through study completion, an average of 1 year. | To evaluate the systemic pharmacokinetics of JMT108 in subjects. |
Countries
China
Contacts
CONTACTClinical Trials Information Group officer
Outcome results
None listed